Liver imaging

  • Radiology. 2019:In press. Gadoxetic Acid-enhanced MRI of Hepatocellular Carcinoma: Value of Washout in Transitional and Hepatobiliary Phases. Kim DH, Choi SH, Kim SY, Kim MJ, Lee SS, Byun JH. PubMed
  • Clin Pharmacol Ther. 2019;105:1062-1064. Imaging P-Glycoprotein function at the Blood-Brain Barrier as a determinant of the variability in response to central nervous system drugs. Bauer M, Tournier N, Langer O. PubMed
  • HPB (Oxford). 2018;pii: S1365-182X(18)34471-X. Scintigraphic liver function and transient elastography in the assessment of patients with resectable hepatocellular carcinoma. Rassam F, Olthof PB, Takkenberg BR, Beuers U, Klümpen HJ, Bennink RJ, van Lienden KP, Besselink MG, Busch OR, Verheij J, van Gulik TM. PubMed
  • Nucl Med Commun. 2019;40:388-392. Stress test of liver function using technetium-99m-mebrofenin hepatobiliary scintigraphy. Rassam F, Cieslak KP, Beuers UHW, van Gulik TM, Bennink RJ. PubMed
  • Eur Radiol. 2019;In press. Comparison between dynamic gadoxetate-enhanced MRI and 99mTc-mebrofenin hepatobiliary scintigraphy with SPECT for quantitative assessment of liver function. Rassam F, Zhang T, Cieslak KP, Lavini C, Stoker J, Bennink RJ, van Gulik TM, van Vliet LJ, Runge JH, Kusuhara FM. PubMed

OATP1B1 function

  • Drug Metab Pharmacokinet. 2018;pii:S1347-4367(18)30077-6. Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers. Mori D, Kashihara Y, Yoshikado T, Kimura M, Hirota T, Matsuki S, Maeda K, Irie S, Ieiri I, Sugiyama Y, Kusuhara H. PubMed
  • Clin Pharmacol Ther. 2019;105:719-729. Use of Physiologically Based Pharmacokinetic Modeling to evaluate the effect of chronic kidney disease on the disposition of hepatic CYP2C8 and OATP1B drug substrates. Tan ML, Zhao P, Zhang L, Ho YF, Varma MVS, Neuhoff S, Nolin TD, Galetin A, Huang SM. PubMed

Transporters and hepatocellular carcinoma

  • J Pharmacol Exp Ther. 2019;368:363-381. Deregulation of the genes that are involved in drug absorption, distribution, metabolism, and excretion in hepatocellular carcinoma. Hu DG, Marri S, McKinnon RA, Mackenzie PI, Meech R. PubMed
  • Anticancer Res. 2019;39:695-701. Chrysin-induced ERK1/2 phosphorylation enhances the sensitivity of Human Hepatocellular Carcinoma cells to Sorafenib. Wei CT, Chen LC, Hsiang YP, Hung YJ, Chien PH, Pan HL, Chen YJ. PubMed

Hepatic clearance

  • Drug Metab Dispos. 2019;47:320-327. Use of segregated hepatocyte scaling factors and cross-species relationships to resolve clearance dependence in the prediction of human hepatic clearance. Hallifax D, Houston JB. PubMed
  • Drug Metab Dispos. 2019;47:484-492. A novel unified approach to predict human hepatic clearance for both enzyme- and transporter-mediated mechanisms using suspended human hepatocytes. Riccardi KA, Tess DA, Lin J, Patel R, Ryu S, Atkinson K, Di L, Li R. PubMed
  • AAPS J. 2019;21:43. Theoretical considerations for direct translation of unbound liver-to-plasma partition coefficient from in vitro to in vivo. Li Z, Di L, Maurer TS. PubMed
  • J Pharmacol Exp Ther. 2019;In press. Quantitative contribution of six major transporters to the hepatic uptake of drugs: 'SLC-phenotyping' using primary human hepatocytes. Bi YA, Costales C, Mathialagan S, West M, Eatemadpour S, Lazzaro S, Tylaska L, Scialis R, Zhang H, Umland J, Kimoto E, Tess DA, Feng B, Tremaine L, Varma MVS, Rodrigues AD. PubMed

Drug-Drug Interactions

  • Clin Pharmacol Ther. 2019;in press. Practical assessment of clinical drug-drug interactions in drug development using physiologically based pharmacokinetics modeling. Shebley M, Einolf HJ. PubMed
  • Clin Pharmacol Ther. 2019;In press. Clinical studies on drug-drug interactions involving metabolism and transport: Methodology, pitfalls and interpretation. Tornio A, Filppula AM, Niemi M, Backman JT. PubMed
  • Drug Metab Dispos. 2019;47:493-503. Mechanistic evaluation of the complex drug-drug interactions of Maraviroc: contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1. Kimoto E, Vourvahis M, Scialis RJ, Eng H, Rodrigues AD, Varma MVS. PubMed


  • Clin Pharmacol Ther. 2018;In press. Induction of mild hyperbilirubinemia: Hype or real therapeutic opportunity? Vitek L, Bellarosa C, Tiribelli C. PubMed

OST α/β transport

  • Biochim Biophys Acta Biomembr. 2019;1861:1023-1029. Characterization of conjugated and unconjugated bile acid transport via human organic solute transporter α/β. Suga T, Yamaguchi H, Ogura J, Mano N. PubMed

Drug hepatotoxicity

  • Pharm Res. 2019;36:48. Analyzing the mechanisms behind macrolide antibiotic-induced liver injury using quantitative systems toxicology modeling. Woodhead JL, Yang K, Oldach D, MacLauchlin C, Fernandes P, Watkins PB, Siler SQ, Howell BA. PubMed


  • Gene Expr. 2019;In press. Blood bile barrier: morphology, regulation and pathophysiology. Pradhan-Sundd T, Monga SP. PubMed
  • Mol Pharmacol. 2019;95:324-334. Belinostat, at its clinically relevant concentrations, inhibits Rifampicin-induced CYP3A4 and MDR1 gene expression. Abbott KL, Chaudhury CS, Chandran A, Vishveshwara S, Dvorak Z, Jiskrova E, Poulikova K, Vyhlidalova B, Mani S, Pondugula SR. PubMed